RCM
RA Capital Management Portfolio holdings
AUM
$5.94B
This Quarter Return
+42.01%
1 Year Return
+18.15%
3 Year Return
+417.5%
5 Year Return
+458.13%
10 Year Return
+21,247.51%
AUM
$6.4B
AUM Growth
+$6.4B
(+26%)
Cap. Flow
+$71M
Cap. Flow
% of AUM
1.11%
Top 10 Holdings %
Top 10 Hldgs %
60.92%
Holding
71
New
5
Increased
8
Reduced
9
Closed
9
Top Buys
| 1 |
IMGN
Immunogen Inc
IMGN
|
$309M |
| 2 |
MacroGenics
MGNX
|
$35.7M |
| 3 |
C4 Therapeutics
CCCC
|
$27.6M |
| 4 |
UroGen Pharma
URGN
|
$24M |
| 5 |
Structure Therapeutics
GPCR
|
$19.8M |
Top Sells
| 1 |
Ascendis Pharma
ASND
|
$77.1M |
| 2 |
Cogent Biosciences
COGT
|
$62.6M |
| 3 |
Soleno Therapeutics
SLNO
|
$36.6M |
| 4 |
Avidity Biosciences
RNA
|
$35.9M |
| 5 |
CureVac
CVAC
|
$33.1M |
Sector Composition
| 1 | Healthcare | 99.98% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Ascendis Pharma
ASND
$11.8B
| $1.27B | 19.88% | 10,107,400 -612,155 | -6% | -$77.1M |
|
|
IMGN
2
DELISTED
Immunogen Inc
IMGN
| $704M | 11% | 23,750,601 +10,428,313 | +78% | +$309M |
|
3
Vaxcyte
PCVX
$4B
| $496M | 7.74% | 7,891,254 | – | – |
|
4
Legend Biotech
LEGN
$6.41B
| $377M | 5.89% | 6,264,707 | – | – |
|
5
Rhythm Pharmaceuticals
RYTM
$6.85B
| $245M | 3.83% | 5,330,412 -345,655 | -6% | -$15.9M |
|
|
JBIO
6
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $187M | 2.92% | 8,263,982 | – | – |
|
|
INBX
7
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $180M | 2.8% | 4,724,207 | – | – |
|
|
CBAY
8
DELISTED
Cymabay Therapeutics
CBAY
| $164M | 2.56% | 6,940,000 | – | – |
|
9
Biogen
BIIB
$19.4B
| $138M | 2.15% | 532,892 | – | – |
|
10
RxSight
RXST
$370M
| $137M | 2.14% | 3,404,285 +351,489 | +12% | +$14.2M |
|
11
89bio
ETNB
$1.34B
| $128M | 1.99% | 11,416,948 | – | – |
|
|
VRNA
12
Verona Pharma
VRNA
$9.16B
| $126M | 1.96% | 6,317,990 | – | – |
|
13
Day One Biopharmaceuticals
DAWN
$769M
| $114M | 1.78% | 7,809,852 | – | – |
|
14
AN2 Therapeutics
ANTX
$30.1M
| $114M | 1.78% | 5,551,295 | – | – |
|
15
Tyra Biosciences
TYRA
$675M
| $100M | 1.57% | 7,236,454 | – | – |
|
16
Janux Therapeutics
JANX
$1.37B
| $98.3M | 1.54% | 9,165,652 | – | – |
|
17
Geron
GERN
$893M
| $97.5M | 1.52% | 46,202,425 | – | – |
|
|
ICVX
18
DELISTED
Icosavax, Inc. Common Stock
ICVX
| $94M | 1.47% | 5,963,565 | – | – |
|
|
ALPN
19
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $93.6M | 1.46% | 4,909,763 +218,585 | +5% | +$4.17M |
|
20
Wave Life Sciences
WVE
$1.53B
| $91.9M | 1.44% | 18,202,009 +1,000,000 | +6% | +$5.05M |
|
21
NewAmsterdam Pharma
NAMS
$2.71B
| $87.8M | 1.37% | 7,864,000 -1,136,000 | -13% | -$12.7M |
|
22
4D Molecular Therapeutics
FDMT
$288M
| $84.3M | 1.32% | 4,163,211 | – | – |
|
23
Evolent Health
EVH
$1.12B
| $84.2M | 1.32% | 2,549,132 -187,548 | -7% | -$6.19M |
|
24
Axsome Therapeutics
AXSM
$6.05B
| $79.6M | 1.24% | 1,000,000 | – | – |
|
25
Fulcrum Therapeutics
FULC
$351M
| $78.4M | 1.22% | 11,609,704 | – | – |
|